Exclusive | FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says
The FDA is reversing its rejection of Regenxbio's gene therapy for Hunter syndrome, marking the third such reversal for rare-disease drugs.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 11.
- Outcome review added Archynetys revisited the signal after coverage cooled.
Source diversity sample: Yahoo Finance · Baton Rouge Business Report · Reuters · BioSpace · Fierce Biotech · Devdiscourse · U.S. News & World Report · Endpoints News.
How this dossier is built: methodology · AI policy · corrections.
📍 How it ended
The FDA reversed its previous rejection of Regenxbio's rare-disease gene therapy for Hunter syndrome. The agency backed a bid for accelerated approval, allowing Regenxbio to resubmit the BLA for NAVSUNLI.
Epilogue added 68d ago, after coverage quieted.
Coverage (13)
- RGNX Retail Investors See Hope As FDA Reopens Door For Regenxbio’s Hunter Syndrome Therapy Yahoo Finance · 71d ago
- REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II Yahoo Finance · 71d ago
- FDA reconsiders rejected rare-disease gene therapy Baton Rouge Business Report · 71d ago
- US FDA reverses course on Regenxbio's rare-disease gene therapy, backs accelerated approval bid Reuters · 71d ago
- REGENXBIO to resubmit application for Hunter gene therapy after FDA’s most recent pivot BioSpace · 71d ago
- In another reversal for rare disease field, FDA to reconsider Regenxbio gene therapy Fierce Biotech · 71d ago
- Reuters US Domestic News Summary Devdiscourse · 71d ago
- US FDA Reverses Course on Regenxbio's Rare-Disease Gene Therapy, Backs Accelerated Approval Bid U.S. News & World Report · 71d ago
- Regenxbio to resubmit Hunter syndrome gene therapy as FDA rare disease about-face continues Endpoints News · 71d ago
- REGENXBIO gets FDA path to resubmit NAVSUNLI for MPS II Stock Titan · 71d ago
- REGENXBIO’s Duchenne Data Keeps Me Bullish, But There’s Less Room For Setbacks Now (RGNX) Seeking Alpha · 71d ago
- FDA reverses course on Regenxbio’s childhood gene therapy after rejection statnews.com · 71d ago
- Exclusive | FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says WSJ · 71d ago
Where it stands
The FDA will allow Regenxbio to resubmit its gene therapy, NAVSUNLI, intended for the treatment of MPS II (Hunter syndrome). This move follows a previous rejection of the childhood gene therapy.
Coverage from the Wall Street Journal, Stat News, Endpoints News, and Stock Titan emphasizes that this represents a continuing 'about-face' by the FDA regarding rare-disease drugs. The Wall Street Journal reports this is the third rare-disease drug rejection the agency has reversed.
Future developments center on the resubmission of the therapy for MPS II. Additionally, Seeking Alpha highlights ongoing attention toward Regenxbio's Duchenne data.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 71d ago.
Answered
What drug is being resubmitted to the FDA?
Regenxbio is resubmitting NAVSUNLI, a gene therapy for MPS II (Hunter syndrome).
How many rare-disease drug rejections has the FDA reversed?
According to the Wall Street Journal, this is the third rare-disease drug rejection the FDA will reverse.
What other data is currently being monitored for Regenxbio?
Coverage from Seeking Alpha indicates that the company's Duchenne data remains a point of focus.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
Walmart mangoes recalled over potential salmonella contamination
Walmart’s popular mangoes are being pulled from shelves after a surprise salmonella risk emerges.
FDA Announces Tofu Recall: More Than 10,000 Cases May Be Contaminated With Ink
The FDA has announced a recall of over 10,000 cases of tofu, potentially contaminated with ink, affecting 29 states.
White jasmine rice recall expands to 13 states months after initial health alert
FDA widens Lundberg white jasmine rice recall to 13 states, covering over 54,000 pounds of potentially contaminated product
Pet food recalled over salmonella, listeria risks
A nationwide recall of nearly 2,000 lb of raw pet food over Salmonella and Listeria has triggered urgent consumer alerts.
Check your cabinets: White rice recalled in 13 states
The FDA has expanded a recall of white rice to 13 states, but the exact nature of the contamination is unclear.
Map Shows States With Impacted IV As Fiberglass Detected in Saline
14 states are affected by a recall of saline bags due to potential fiberglass contamination
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.